Safety and value driving Phase IV growth at CROs; EVP

Safety and value driving Phase IV growth at CROs; EVP

5 Minuten

Beschreibung

vor 15 Jahren
Increased focus on post-market safety and value has resulted in
CROs handling more Phase IV work, according to a PharmaNet EVP, and
this trend may continue as regulators seek real world evidence.

Kommentare (0)

Lade Inhalte...

Abonnenten

15
15